drugset / Trial / NCT04085367

Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face

NCT04085367

Phase 3 Completed 557 enrolled Galderma R&D
RandomizedParallel-groupTriple-blindTreatment

Summary

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (DL-PDT).

Timeline

Start
2019-09-30
Primary completion
2021-03-03
Completion
2021-04-07

Drugs

EvaluationDrugModalityDoseRoute
Subject methyl aminolevulinate Small molecule 16.8 %

Indications